Neurocern Demonstrates $370M in Savings for Medicare and Health Insurance Using Artificial Intelligence and Data Analytics Targeted at Alzheimer’s Disease Drug Eligibility

(CHICAGO, IL) — Neurocern announced today a savings outcome of $370M over five years by leveraging artificial intelligence (AI) and neuroinformatics to guide patients to the right Alzheimer’s treatment at the right time. As new disease modifying treatments for Alzheimer’s disease continue to emerge, Medicare and private health insurance plans need data-driven methods to screen, identify, and guide patients to…

Finding Cognitive Risk Using Medicare Supplement Data and Predictive Analytics

In today’s world, data is king. At Neurocern, we process millions of data fields to find clinical insights. For Medicare supplement data, that means improving risk adjustment accuracy and quality of care. Neurological diseases are the leading cause of disability globally, the second leading cause of death, and a top three condition in health mortality assumptions.  As a result, there…